ATOMS (Adjustable Trans-Obturator Male System) in Patients with Post-Prostatectomy Incontinence and Previously Treated Urethral Stricture or Bladder Neck Contracture.

adjustable trans-obturator male system artificial urinary sphincter fixed male sling sling failure stress urinary incontinence

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
19 Aug 2022
Historique:
received: 02 07 2022
revised: 09 08 2022
accepted: 16 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

(1) Background: Male stress incontinence in patients with previously treated urethral or bladder neck stricture is a therapeutic challenge. The efficacy and safety of the adjustable trans-obturator male system (ATOMS) in these patients is unknown. (2) Methods: All patients with primary ATOMS implants in our institution between 2014 and 2021 were included. The outcomes of patients with previously treated urethral or bladder neck stricture (≥6 months before ATOMS implant) and stable 16Ch urethral caliber were compared to those without a history of stricture. The primary endpoint was the dry patient rate, defined as the pad test ≤ 20 mL/day, and complication rate, including device removal. The secondary variable was self-perceived satisfaction using the Patient Global Impression of Improvement (PGI-I) scale. Wilcoxon rank sum test, Fisher’s exact test and logistic regression were performed. (3) Results: One hundred and forty-nine consecutive patients were included, twenty-one (14%) previously treated for urethral or bladder neck stricture (seven urethroplasty, nine internal urethrotomy and five bladder neck incision). After ATOMS adjustment, 38% of the patients with treated stricture were continent compared to 83% of those without (p < 0.0001). After weighted matched observations using propensity score pairing, the proportion of continent patients without a previous stricture was 56% (p = 0.236). Complications occurred in 29% of the patients with stricture and in 20% of those without (p = 0.34). The severity of the complications was distributed evenly among the groups (p = 0.42). Regarding self-perceived satisfaction with the implant, 90% of the patients with stricture perceived the results satisfactorily (PGI-I 1−3) compared to 97% of the rest (p = 0.167). Stricture was associated with radiotherapy (p < 0.0001) and time from prostatectomy to implantation (p = 0.012). There was a moderate correlation between previous stricture and the severity of incontinence, both evaluated according to the 24-h pad test (Rho = 0.378; p < 0.0001) and the ICIQ-SF questionnaire (Rho = 0.351; p < 0.0001). Multivariate analysis for the factors predictive of failure after ATOMS adjustment revealed previous stricture (OR 4.66; 95% CI 1.2−18.87), baseline 24-h pad test (per 100 mL, OR 1.28; 95% CI 1.09−1.52) and final cushion volume (per mL, OR 1.34; 95% CI 1.19−1.55). This model predicted dryness with an AUC of 92%. After the PSMATCH procedure using a propensity score, the model remained unchanged, with the previous stricture (OR 8.05; 95% CI 1.08−110.83), baseline 24-h pad test (per 100 mL, OR 1.53; 95% CI 1.15−2.26) and final cushion volume (per mL, OR 1.45; 95% CI 1.17−2) being independent predictors and an AUC of 93%. (4) Conclusions: ATOMS can be used to treat male stress incontinence in patients with a history of stricture, although the effectiveness of the device is reduced. On the other hand, the security and perceived satisfaction were equivalent for both groups.

Identifiants

pubmed: 36013121
pii: jcm11164882
doi: 10.3390/jcm11164882
pmc: PMC9410097
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Adv Ther. 2017 May;34(5):1173-1183
pubmed: 28405960
World J Urol. 2019 Apr;37(4):647-653
pubmed: 30656494
Can Urol Assoc J. 2022 May;16(5):E256-E260
pubmed: 34941490
Urol Clin North Am. 2017 Feb;44(1):93-103
pubmed: 27908376
Urology. 2008 Oct;72(4):825-7
pubmed: 18752838
Urol Int. 2018;101(1):106-113
pubmed: 29953998
J Urol. 2012 Mar;187(3):951-5
pubmed: 22264456
Urology. 2015 Sep;86(3):618-24
pubmed: 26135812
J Urol. 2014 Dec;192(6):1756-61
pubmed: 25014577
Urology. 2014 Oct;84(4):934-8
pubmed: 25109562
Neurourol Urodyn. 2020 Aug;39(6):1737-1745
pubmed: 32496606
World J Urol. 2021 Dec;39(12):4449-4457
pubmed: 34272596
J Urol. 2015 Dec;194(6):1692-6
pubmed: 26141851
Adv Ther. 2021 Jan;38(1):678-690
pubmed: 33230712
J Urol. 2012 Mar;187(3):956-61
pubmed: 22264469
J Pers Med. 2022 Jan 12;12(1):
pubmed: 35055409
J Urol. 2019 Nov;202(5):1022-1028
pubmed: 31251715
Urology. 2021 Feb;148:280-286
pubmed: 33181122
J Clin Med. 2021 Dec 24;11(1):
pubmed: 35011821
Adv Ther. 2019 Feb;36(2):426-441
pubmed: 30560525
Neurourol Urodyn. 2021 Mar;40(3):897-909
pubmed: 33645867
Neurourol Urodyn. 2022 Feb;41(2):609-615
pubmed: 34969148
World J Urol. 2020 Jan;38(1):183-191
pubmed: 30980093
BJU Int. 2017 May;119(5):785-792
pubmed: 27868328
Neurourol Urodyn. 2018 Apr;37(4):1458-1466
pubmed: 29315765

Auteurs

Ane Ullate (A)

Clinical Department, Faculty of Biomedical Science, Universidad Europea, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.

Ignacio Arance (I)

Clinical Department, Faculty of Biomedical Science, Universidad Europea, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.
Department of Urology, Hospital Universitario de Getafe, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.

Miguel Virseda-Chamorro (M)

Department of Urology, Hospital Nacional de Parapléjicos, Carretera de la Peraleda, S/N, 45004 Toledo, Spain.

Sonia Ruiz (S)

Department of Urology, Hospital Universitario de Getafe, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.

Juliusz Szczesniewski (J)

Department of Urology, Hospital Universitario de Getafe, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.

Carlos Téllez (C)

Department of Urology, Hospital Universitario de Getafe, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.

Fabian Queissert (F)

Department of Urology and Pediatric Urology, University Hospital Muenster, 48143 Muenster, Germany.

Juan F Dorado (JF)

PeRTICA Statistical Solutions, Av. Leonardo Da Vinci, 8, OF217, Getafe, 28906 Madrid, Spain.

Javier C Angulo (JC)

Clinical Department, Faculty of Biomedical Science, Universidad Europea, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.
Department of Urology, Hospital Universitario de Getafe, Carretera de Toledo, Km 12.500, Getafe, 28905 Madrid, Spain.

Classifications MeSH